Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01174563 | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 |
| clinicaltrials |
| NCT00638937 | AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01871805 | A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Aug 21, 2018 | clinicaltrials |
| NCT01207063 | Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 40 | Maastricht Radiation OncologyOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00654420 | A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT01922583 | AUY922 in Patient With Stage IV NSCLC(NSCLC) | completed | Phase 2 | 31 | National Taiwan University HospitalOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02005458 | Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 80 | Xiamen Amoytop Biotech Co., Ltd.INDUSTRY | 1 | Jul 17, 2018 | clinicaltrials |
| NCT02025114 | Selumetinib in Combination With Gefitinib in NSCLC Patients | completed | Phase 1 / Phase 2 | 34 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT00890825 | AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | completed | Phase 2 | 88 | AstraZenecaINDUSTRY | 12 | Jun 20, 2018 | clinicaltrials |
| NCT01864681 | Combination of Metformin With Gefitinib to Treat NSCLC(CGMT) | completed | Phase 2 | 224 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT01829113 | Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer(Spruce) | completed | Phase 2 | 155 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00870870 | A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00687297 | Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 162 | PrECOG, LLC.OTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02979821 | Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | completed | Phase 2 | 6 | Korean Association for the Study of Targeted TherapyOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01139775 | A Study in Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 76 | Eli Lilly and CompanyINDUSTRY | 2 | May 18, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT01029678 | Concomitant Radio-chemotherapy in the Elderly(RACCOSA) | completed | Phase 2 | 48 | University Hospital, LimogesOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT00078390 | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | ShionogiINDUSTRY | 1 | May 2, 2018 | clinicaltrials |
| NCT01588145 | Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | completed | Phase 1 / Phase 2 | 273 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02444819 | Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy | completed | Phase 2 | 33 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00266877 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Puma Biotechnology, Inc.INDUSTRY | 5 | Apr 13, 2018 | clinicaltrials |
| NCT00410904 | AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2018 | clinicaltrials |
| NCT01854034 | Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | completed | Phase 2 | 29 | Massachusetts General HospitalOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00654030 | Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer | completed | Phase 2 | 12 | Edward HirschowitzOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT00111839 | Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer | completed | Phase 2 | 150 | EMD SeronoINDUSTRY | 3 | Apr 6, 2018 | clinicaltrials |
| NCT01395758 | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 96 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 3, 2018 | clinicaltrials |
| NCT01752400 | AUY922 for Advanced ALK-positive NSCLC | completed | Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT00923312 | Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 46 | CureVacINDUSTRY | 2 | Mar 20, 2018 | clinicaltrials |
| NCT00462995 | Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)(SELECT) | completed | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00997334 | Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | completed | Phase 2 | 60 | David M. Jackman, MDOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00399789 | A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | AEterna ZentarisINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00072631 | Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 43 | OSI PharmaceuticalsINDUSTRY | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00138203 | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01378962 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) | completed | Phase 2 | 50 | Hoffmann-La RocheINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00577707 | Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON) | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01676714 | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | completed | Phase 2 | 10 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00400803 | Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer | completed | Phase 2 | 38 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02182050 | Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer | completed | Phase 2 | 73 | Boehringer IngelheimINDUSTRY | 0 | Dec 28, 2017 | clinicaltrials |
| NCT00230126 | OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer | completed | Phase 2 | 57 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 26, 2017 | clinicaltrials |
| NCT03371550 | A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy(TAXCIS) | completed | Phase 2 | 44 | Centre Antoine LacassagneOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00093756 | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00362882 | Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00783705 | Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia | completed | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 2 | Dec 5, 2017 | clinicaltrials |
| NCT01648517 | Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy | completed | Phase 2 | 60 | Yonsei UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 17, 2018source: clinicaltrials